TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00419471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
Study: NCT04206878

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care birth test
Description: Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
Study: NCT03399266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Balloon catheter for induction of labor
Description: With the patient in lithotomy position or lying supine in bed, a speculum is inserted to visualise the cervix. The device is inserted into the cervix using long forceps until both balloons enter the cervical canal. Then, the uterine balloon is inflated with 20 ml of saline (by means of a 20 ml syringe). The device is then pulled out until stopped by the uterine balloon covering the internal cervical os. At this point the cervico-vaginal balloon located at the external os is inflated with 20 ml of saline and the speculum is removed. Then both balloons are additionally inflated with alternate increments of 20 ml normal saline to a total volume of 80 ml in each balloon. The device is loosely taped to the patient's inner thigh.
Study: NCT03690310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR NK Cells
Description: Anti-CD19 CAR NK Cells injection
Study: NCT00364689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT06536452

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT01748604

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Lymphatic Drainage (MLD)
Description: MLD with Földi's technique by an expert therapist during 45 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic intermittent pneumatic compression Device (IPC)
Description: Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Generic intermittent pneumatic compression Device (IPC)
Description: Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic intermittent pneumatic compression Device (IPC)
Description: Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multilayer, multicomponent bandages (MB)
Description: multilayer, multicomponent bandages (MB) until next day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multilayer, multicomponent bandages (MB)
Description: multilayer, multicomponent bandages (MB) until next day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multilayer, multicomponent bandages (MB)
Description: multilayer, multicomponent bandages (MB) until next day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lymphapress-Plus(TM) device (LPD)
Description: Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
Study: NCT04755517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequent information of cytological/ HPV DNA screening results
Description: All participants will be referred to pertinent diagnosis and treatment according to local standard of care (Käypä hoito 2010) should the cytological screening results (HSIL, ASC-H, AGC-FN) or three consecutive LSIL findings at repeated control visits within 3 years indicate it. The most common screening results (ASCUS, LSIL) are, however, not convened to arm A2 participants before age 28.~All cytology and HPV DNA results results are being revealed to all trial participants at age 28 at the study end.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequent information of cytological/ HPV DNA screening results
Description: All participants will be referred to pertinent diagnosis and treatment according to local standard of care (Käypä hoito 2010) should the cytological screening results (HSIL, ASC-H, AGC-FN) or three consecutive LSIL findings at repeated control visits within 3 years indicate it. The most common screening results (ASCUS, LSIL) are, however, not convened to arm A2 participants before age 28.~All cytology and HPV DNA results results are being revealed to all trial participants at age 28 at the study end.
Study: NCT01171898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509 (Phase 1)
Description: ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509 (Phase 2)
Description: ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509 (Phase 2)
Description: ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
Study: NCT03758755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction rehabilitation
Description: post-operative rehabilitation according to current standards of care
Study: NCT01171898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509 (Phase 2)
Description: ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
Study: NCT04458051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Film-coated Tablet Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Film-coated Tablet Route of administration: Oral
Study: NCT02630901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX003

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01590173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone and Heparin during COH for IVF
Description: Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
Study: NCT03513341

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is given to the participants. This is an observational study exploring the students' levels of physical activity and sedentary behaviour in their natural setting.
Study: NCT04253886

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ovassapian Fibreoptic Intubating Airway
Description: The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ovassapian Fibreoptic Intubating Airway
Description: The fibreoptic bronchoscope remains one of the most important methods of intubating patients particularly when there is difficulty with intubation.Facilitating fiberoptic oropharyngeal intubation procedure, specific airways have been devised to push the tongue anteriorly to clear a passage for the fibrescope into the trachea. Of these airways Ovassapian Fibreoptic Intubating Airway (Kendall, Argyle, New York, New York, USA) and Fekry Oral Intubating Airway (Ameco Tech, Cairo, Egypt).
Study: NCT01267357

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT03893695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT90001 and Nivolumab
Description: Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
Study: NCT02193906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo task
Description: Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
Study: NCT03217253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study: NCT01590173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COH for IVF
Description: Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
Study: NCT02701673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 60 mg/m2 by vein on Days -3 and -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell transplant performed on Day 0.
Study: NCT00808743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib: 400mg twice daily, orally, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib: 400mg twice daily, orally, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses
Study: NCT03927482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARES mobile smart phone app
Description: The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Check Your Drinking
Description: Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
Study: NCT03959423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHCL insulin pump system
Description: 670G 4.0 system with GS3; 780G system with G4S (continued access phase);
Study: NCT02133300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Study: NCT01362010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Minocycline Foam FXFM244
Description: Topically applied once a day.
Study: NCT03669315

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic stimulation
Description: Neuromodulation tool

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic stimulation
Description: Neuromodulation tool
Study: NCT01790503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT00510809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Policosanol
Description: Policosanol 20 mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Policosanol Plus Already In Use Statin Therapy
Description: Policosanol 20 mg daily Statin Therapy
Study: NCT00070941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-e
Description: oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo escitalopram.
Study: NCT01787058

Intervention type: OTHER
Intervention: Dubai Cares beneficiary
Description: Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
Study: NCT01798836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist or antagonist protocol without oestradiol pre-treatment
Study: NCT01474668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Single oral dose\\n \\n\\n\\n\\n
Study: NCT02865564

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ampicillin and gentamicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ampicillin and gentamicin
Study: NCT03947242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib and Trastuzumab plus Vinorelbine
Description: Pyrotinib:400mg orally daily Trastuzumab:8mg/kg ivgtt load followed by 6mg/kg ivgtt 3-weekly for a total of 4 cycles Vinorelbine :25mg/m2 ivgtt 3-weekly for a total of 4 cycles,d1 d8
Study: NCT03806803

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized fecal microbiota transplant
Description: 15 capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized sterile fecal filtrate
Description: 15 capsules
Study: NCT02543671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3 enriched, reduced-fat yellow cheese
Description: 60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: plain (non-fortified) reduced-fat yellow cheese
Description: 60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
Study: NCT01938547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Study: NCT02215083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: 10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
Study: NCT05844722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention therapy
Description: Mindfulness-based cognitive therapy consists of meditation techniques to stay in the present moment with acceptance (breathing exercises, body scan, gentle yoga, awareness of thoughts and feelings) and some aspects of cognitive therapy, and psycho-education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual care means received standard multidisciplinary stroke care
Study: NCT01362010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minocycline Foam FXFM244
Description: Topically applied once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minocycline Foam FXFM244
Description: Topically applied once a day.
Study: NCT03571698

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Stimulator
Description: The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Stimulator
Description: The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
Study: NCT01702636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03053206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADE Protocol
Description: ADE chemotherapy~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days
Study: NCT02380768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain (size 1.5 or size 2.0)
Description: The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme (size 1.5 or size 2.0)
Description: The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
Study: NCT03389048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMD-200
Description: The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SLR
Description: With the patient lying down on his/her back, the examiner lifts the patient's leg while the knee is straight.
Study: NCT00070941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral escitalopram
Description: 20mg or 30mg daily in two divided doses, along with placebo SAM-e.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
Study: NCT03881969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Payment of £100
Description: No financial payment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Payment of £100
Description: No financial payment